Abuse-Deterrent Testimony: Hamburg Defends Opioid Policy On The Hill
This article was originally published in The Pink Sheet Daily
“It doesn’t do any good to label something as abuse-deterrent if it actually isn’t,” the FDA Commissioner tells senators. “And right now, unfortunately, the technology is poor.”
You may also be interested in...
Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?
The acting US FDA commissioner equates drug development in the neurodegenerative diseases to work on HIV.
Supplement approval timeline and regulatory science issues apparently have been resolved.